Abstracts Archive - Page 2040 of 2607 - ACR Meeting Abstracts

Abstract Number: 2932 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Deep Vein Thrombosis and Pulmonary Embolism in Sjögren’s Syndrome: A General Population-Based Cohort Study
Marko Yurkovich¹, Hyon K. Choi², Eric C. Sayre³, Kamran Shojania⁴ and J. Antonio Avina-Zubieta⁵, ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Boston University School of Medicine, Boston, MA, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: There is limited data available on the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in Sjögren's Syndrome (SjS). We estimated the…
Abstract Number: 2933 • 2014 ACR/ARHP Annual Meeting
Metabolic Syndrome, Adipocytokines and Inflammation in Sjögren’s Syndrome
Kristopherson Lustosa Augusto¹, Eloisa Bonfá², Rosa M. R. Pereira¹, Cleonice Bueno³, Vilma S. T. Viana⁴ and Sandra G. Pasoto⁵, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, ³Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose Systemic inflammation has been linked to increased frequency of metabolic syndrome (MetS) in autoimmune diseases. However, there are no studies concerning the frequency of…
Abstract Number: 2934 • 2014 ACR/ARHP Annual Meeting
Abatacept reduces Circulating Effector Memory T-Helper Cells in Patients with Primary Sjögren’s Syndrome
Gwenny Verstappen¹, Wayel H. Abdulahad², Petra M. Meiners³, Suzanne Arends⁴, Silvia Beijer-Liefers⁵, Arjan Vissink³, Frans G.M. Kroese⁴ and Hendrika Bootsma⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose In an open-label proof of concept study, Abatacept has been identified as an effective and safe treatment modality in primary Sjögren’s syndrome (pSS). Abatacept…
Abstract Number: 2935 • 2014 ACR/ARHP Annual Meeting
Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis
Barry J. Sheane¹, Arane Thavaneswaran², Dafna D. Gladman² and Vinod Chandran², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Methotrexate (MTX) is used as first-line treatment in psoriatic arthritis (PsA); however, the extent of the disease-modifying effect of MTX on PsA, if any,…
Abstract Number: 2895 • 2014 ACR/ARHP Annual Meeting
Habitual Running Any Time in Life Is Not Detrimental and May be Protective of Symptomatic Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Grace H. Lo¹, Jeffrey B. Driban², Andrea Kriska³, Kristi Storti³, Timothy E. McAlindon⁴, Richard Souza⁵, Charles B. Eaton⁶, Nancy J. Petersen⁷ and Maria E. Suarez-Almazor⁸, ¹VA HSR&D Center for Innovations in Quality, Effectiveness and Safety; Medical Care Line and Research Care Line; Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, ²Tufts Medical Center, Boston, MA, ³University of Pittsburgh, Pittsburgh, PA, ⁴Division of Rheumatology, Tufts Medical Center, Boston, MA, ⁵University of California, San Francisco, San Francisco, CA, ⁶Family Medicine, Memorial Hospital of Rhode Island, Pawtucket, RI, ⁷Medicine, Baylor College of Medicine, Houston, TX, ⁸The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose Controversy exists regarding whether habitual running is beneficial versus harmful to the knee. Chronic mechanical overloading could potentially physically damage structures within the knee. …
Abstract Number: 2896 • 2014 ACR/ARHP Annual Meeting
a Multi-Center Double-Blind, Randomized, Controlled Trial (db-RCT) to Evaluate the Effectiveness and Safety of Co-Administered Traumeel^® (Tr14) and Zeel^® (Ze14) Intra‑articular (IA) Injections Versus IA Placebo in Patients with Moderate-to-Severe Pain Associated with OA of the Knee
Carlos Lozada¹, Eve del Rio², Donald Reitberg², Robert Smith², Charles Kahn³ and Roland W. Moskowitz⁴, ¹Rheumatology, University of Miami Miller School of Medicine, Miami, FL, Miami, FL, ²Clinical Research, Rio Pharmaceutical Services, LLC, Bridgewater, NJ, ³South Florida Rheumatology, Hollywood, FL, ⁴Div of Rheum/Dept of Medicine, University Hospitals Case Medical Center, Cleveland, OH
Background/Purpose: Tr14 & Ze14 is a combination of dilute biological and mineral extracts administered IA for painful knee OA. In response to clinician impressions of…
Abstract Number: 2897 • 2014 ACR/ARHP Annual Meeting
Exercise Therapy and/or Manual Therapy for Hip or Knee Osteoarthritis: 2-Year Follow-up of a Randomized Controlled Trial
J. Haxby Abbott¹, Cathy Chapple², Daniel Pinto³, Alexis Wright⁴ and Jean-Claude Theis⁵, ¹Centre for Musculoskeletal Outcomes Research, Department of Surgical Sciences, University of Otago, Dunedin, New Zealand, ²School of Physiotherapy, University of Otago, Dunedin, New Zealand, ³Department of Physical Therapy & Human Movement Sciences, Northwestern University, Chicago, IL, ⁴Department of Physical Therapy, High Point University, High Point, NC, ⁵Centre for Musculoskeletal Outcomes Research, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
Background/Purpose: Although both exercise therapy and manual therapy have evidence supporting their effectiveness in people with hip and knee osteoarthritis (OA), few clinical trials have…
Abstract Number: 2898 • 2014 ACR/ARHP Annual Meeting
New Insights into the Primary Care Osteoarthritis Consultation with Implications for Practice
Zoe Paskins¹, Tom Sanders¹, Peter Croft¹ and Andrew Hassell², ¹Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ²School of Medicine, Keele University, Keele, United Kingdom
Background/Purpose Osteoarthritis (OA) is the commonest long term condition in primary care. Existing international guidance suggests that much can be done to improve patient outcomes…
Abstract Number: 2899 • 2014 ACR/ARHP Annual Meeting
High Dose Aspirin for Treating Kawasaki Disease – Outdated Myth or Effective Aid?
Gil Amarilyo¹, Yael Koren², Dafna Brik Simon³, Maskit Bar-Meir⁴, Hilla Bahat⁵, Mona Hanna Helou⁶, Amir Mendelson⁷, Yackov Berkun⁸, Eli Eisenstein⁹, Yonatan butbul Aviel¹⁰, Galia Barkai¹¹, Yoav Bolkier¹¹, Shai Padeh¹¹, Philip J. Hashkes¹², Riva Brik¹⁰, Liora Harel¹ and Yosef Uziel¹³, ¹Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Schneider Children's Medical Center of Israel, Petach Tikvah, Israel, ⁴Infectious Diseases, Shaare-Zedek Medical Center, Jerusalem, Israel, ⁵Pediatrics, Assaf Harofeh Medical Center, Zerifin, Israel, ⁶Pediatrics B Department, Rambam Medical Center, Haifa, Israel, ⁷Pediatric Rheumatology, Meir Medical Center, Kfar Saba, Israel, ⁸Pediatrics and Pediatric Rheumatology, Hadassah Hebrew University Medical Center, Jerusalem, Israel, ⁹Dept of Pediatrics, Hadassah Hebrew University Medical Center, Jerusalem, Israel, ¹⁰Pediatric Rheumatology, Rambam Medical Center, Haifa, Israel, ¹¹Sheba Medical Center, Tel-Hashomer, Israel, ¹²Pediatrics, Shaare-Zedek Medical Center, Jerusalem, Israel, ¹³Pediatric Rheumatology Unit , Department of Pediatrics, Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Kawasaki disease (KD) is generally treated with intravenous immunoglobulin (IVIG) together with high anti-inflammatory doses of acetyl salicylic acid (ASA), which is subsequently switched…
Abstract Number: 2900 • 2014 ACR/ARHP Annual Meeting
Clinically Inactive Disease in Juvenile Dermatomyositis – a Proposed Revision to the Pediatric Rheumatology International Trials Organisation Criteria
Beverley Almeida¹, Raquel Campanilho-Marques², Katie Arnold², Lucy R. Wedderburn^3,4, Clarissa A Pilkington⁵ and Kiran Nistala⁶, ¹Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ²Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, ³Institute of Child Health, University College London, London, United Kingdom, ⁴Arthritis Research UK Centre for Adolescent Rheumatology,, UCL, UCLH, GOSH NHS Trust, London, United Kingdom, ⁵Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁶Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) affects 3 children/million/year with myositis and skin disease being the typical features. The Pediatric Rheumatology International Trials Organisation (PRINTO) have recently…
Abstract Number: 2901 • 2014 ACR/ARHP Annual Meeting
Predictors of Relapse after Discontinuing Systemic Treatment in Childhood Autoimmune Chronic Uveitis
Gabriele Simonini¹, Claudia Bracaglia², Marco Cattalini³, Andrea Taddio⁴, Alice Brambilla⁵, Cinzia DeLibero⁶, Denise Pires Marafon⁷, Roberto Caputo⁶ and Rolando Cimaz¹, ¹Pediatric Rheumatology, Anna Meyer Children's Hospital-University of Firenze, Florence, Italy, ²Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ³Pediatric Clinic, Spedali Civili di Brescia and University of Brescia, Pediatric Immunology and Rheumatology Unit, Brescia, Italy, ⁴Institute of Child Health, IRCCS Burlo Garofolo, University of Trieste, Trieste, Italy, ⁵Anna Meyer Children's Hospital-University of Firenze, Florence, Italy, ⁶Ophthalmology Unit, Anna Meyer Children's Hospital, Florence, Italy, ⁷Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
Background/Purpose Information regarding the natural clinical history of a child on systemic treatment due to auto-immune chronic uveitis would be helpful in driving duration therapy.…
Abstract Number: 2902 • 2014 ACR/ARHP Annual Meeting
The Health Status of Patients with Juvenile Idiopathic Arthritis (JIA) Significantly Worsens after Transfer from Pediatric to Adult Care
Kirsten Minden¹, Jens Klotsche², Martina Niewerth², Angela Zink³ and Gerd Horneff⁴, ¹Chidlrens´ hospital, Charité University Medicine, Berlin, Germany, ²Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ³German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany
Background/Purpose A minority of patients with polyarticular JIA enter adulthood in drug free remission. Thus, patients are in need of care beyond adolescence. There is…
Abstract Number: 2903 • 2014 ACR/ARHP Annual Meeting
Early Outcomes in Pediatric Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV)
Kimberly Morishita¹, Susanne Benseler², Rae S.M. Yeung³, Thomas Mason II⁴, Dawn Wahezi⁵, Kenneth N. Schikler⁶, Erica F. Lawson⁷, Susan Nielsen⁸, Sirirat Charuvanij⁹, Paul Dancey¹⁰, Susan Shenoi¹¹, Linda Wagner-Weiner¹², Angelyne Sarmiento¹, David A. Cabral¹³ and For the PedVas Initiative¹, ¹BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ²Pediatrics/Alberta Children's Hospital, Department of Pediatrics/University of Calgary, Calgary, AB, Canada, ³Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology - Department of Medicine, Mayo Clinic, Rochester, MN, ⁵Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ⁶Department of Pediatrics, Univ of Louisville Schl of Med, Louisville, KY, ⁷Pediatrics, University of California, San Francisco, San Francisco, CA, ⁸Pediatric rheumatology, Rigshospitalet, Copenhagen, Denmark, ⁹Pediatrics, Siriraj Hospital, Bangkok, Thailand, ¹⁰Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, ¹¹Pediatric Rheumatology, Seattle Childrens Hospital, seattle, WA, ¹²Pediatric Rheumatology, University of Chicago Hospital, Chicago, IL, ¹³Pediatrics, BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Childhood AAV is rare and outcome studies are limited. The PedVas Study is an international initiative collecting clinical data (to A Registry of Childhood…
Abstract Number: 2904 • 2014 ACR/ARHP Annual Meeting
Clinical and Radiological Features of Down’s Arthropathy
Charlene Foley, Orla Killeen and Emma Jane MacDermott, The National Centre for Paediatric Rheumatology, Dublin, Ireland
Background/Purpose The ‘Arthropathy of Down syndrome’ was first described in 1984. Three decades on we still have limited literature on the clinical & radiological features…
Abstract Number: 2905 • 2014 ACR/ARHP Annual Meeting
The IL-6/Th17 Axis Promotes Autoantibody-Associated Autoimmune Valvular Carditis in Mice
Jennifer L. Auger¹, Brianna J. Engelson², Yaya Wang³, Erik J. Peterson⁴ and Bryce A. Binstadt⁵, ¹Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, ²Pediatrics, University of Minnesota, Minneapolis, MN, ³Medicine, University of Minnesota, Minneapolis, MN, ⁴University of Minnesota, Minneapolis, MN, ⁵Pediatric Rheumatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Autoimmune valvular carditis occurs in patients with systemic lupus erythematosus, rheumatoid arthritis and rheumatic fever, but the pathogenic mechanisms remain incompletely defined. Spontaneous autoimmune…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].